Skip to main content

Table 1 Patient baseline characteristics by group

From: Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial

  Pre-Intervention Post-Intervention
  Active (n = 33) Control (n = 36) Active (n = 23) Control (n = 29)
Males (%) 62% 51%   
Age (years) 61 (10) 66 (13)   
Prescribed levodopa (%) 21 (62%) 25 (71%) 18 (78%) 22 (76%)
Levodopa dose (mg) 485 (252) 538 (389) 511 (306) 670 (380)
Prescribed dopamine agonist (%) 25 (74%) 25 (71%) 18 (78%) 18 (62%)
Change in levodopa equivalent units - - 51 (148) 70 (149)
Number of PD drugs 2.4 (1.1) 2.4 (1.3) 2.4 (1.2) 2.2 (1.5)
Number of PD daily doses 4.0 (2.5) 4.0 (1.3) 4 (0.8) 4 (1.2)
Number of PD tablets per day 9 (5) 9.1 (5) 9.5 (5) 9 (5)
Number of non-PD drugs per day 2.6 (3) 2.9 (1.8) 2.5 (3) 3.5 (4)
Total number of tablets per day 12 (5) 12 (5) 13 (7) 12 (7)
Number of patients with carer 6 (18%) 7 (19%)   
Duration of PD (years) 7.5 (6) 6.3 (4.1) - -
UPDRS 3 30 (12) 24 (13) 29 (14) 28 (14)
Hoehn & Yahr 2.4 (0.7) 2.4 (0.7) 2.5 (0.7) 2.5 (0.7)
Schwab & England 78 (10) 76 (14) 71 (18) 73 (15)
MMSE 28 (2) 28 (2) - -
Geriatric depression score 12 (6) 10 (7) - -
PDQ SI 30 (15) 26.5 (18) 36 (15) 28 (14)
Timing adherence, median (IQ) 17% (9–51) 21% (10–59) 39% (22–58) 20% (10–47)*
  1. Data are mean (standard deviation) unless otherwise stated. PD = Parkinson's disease, UPDRS = Unified Parkinson's disease rating scale, MMSE = mini mental state examination, PDQ 39 SI = Parkinson's disease quality of life single index, IQ = interquartile range. *p = 0.007. There were no other significant differences between groups.